Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was observed. Using a comprehensive translational approach, we unravel the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies. Convalescent plasma is safe, does not improve survival, has no effect on the disease course, nor does plasma enhance viral clearance in the respiratory tract, influence SARS-CoV-2 antibody development or serum proinflammatory cytokines levels. Here, we show that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors. This resulted in the decision to terminate the trial prematurely. Treatment with convalescent plasma should be studied early in the disease course or at least preceding autologous humoral response development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nature communications - 12(2021), 1 vom: 27. Mai, Seite 3189 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 10.06.2021 Date Revised 02.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-021-23469-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325942498 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325942498 | ||
| 003 | DE-627 | ||
| 005 | 20240402233214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-021-23469-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM325942498 | ||
| 035 | |a (NLM)34045486 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gharbharan, Arvind |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2021 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was observed. Using a comprehensive translational approach, we unravel the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies. Convalescent plasma is safe, does not improve survival, has no effect on the disease course, nor does plasma enhance viral clearance in the respiratory tract, influence SARS-CoV-2 antibody development or serum proinflammatory cytokines levels. Here, we show that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors. This resulted in the decision to terminate the trial prematurely. Treatment with convalescent plasma should be studied early in the disease course or at least preceding autologous humoral response development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 700 | 1 | |a Jordans, Carlijn C E |e verfasserin |4 aut | |
| 700 | 1 | |a GeurtsvanKessel, Corine |e verfasserin |4 aut | |
| 700 | 1 | |a den Hollander, Jan G |e verfasserin |4 aut | |
| 700 | 1 | |a Karim, Faiz |e verfasserin |4 aut | |
| 700 | 1 | |a Mollema, Femke P N |e verfasserin |4 aut | |
| 700 | 1 | |a Stalenhoef-Schukken, Janneke E |e verfasserin |4 aut | |
| 700 | 1 | |a Dofferhoff, Anthonius |e verfasserin |4 aut | |
| 700 | 1 | |a Ludwig, Inge |e verfasserin |4 aut | |
| 700 | 1 | |a Koster, Adrianus |e verfasserin |4 aut | |
| 700 | 1 | |a Hassing, Robert-Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Bos, Jeannet C |e verfasserin |4 aut | |
| 700 | 1 | |a van Pottelberge, Geert R |e verfasserin |4 aut | |
| 700 | 1 | |a Vlasveld, Imro N |e verfasserin |4 aut | |
| 700 | 1 | |a Ammerlaan, Heidi S M |e verfasserin |4 aut | |
| 700 | 1 | |a van Leeuwen-Segarceanu, Elena M |e verfasserin |4 aut | |
| 700 | 1 | |a Miedema, Jelle |e verfasserin |4 aut | |
| 700 | 1 | |a van der Eerden, Menno |e verfasserin |4 aut | |
| 700 | 1 | |a Schrama, Thijs J |e verfasserin |4 aut | |
| 700 | 1 | |a Papageorgiou, Grigorios |e verfasserin |4 aut | |
| 700 | 1 | |a Te Boekhorst, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Swaneveld, Francis H |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Yvonne M |e verfasserin |4 aut | |
| 700 | 1 | |a Schreurs, Marco W J |e verfasserin |4 aut | |
| 700 | 1 | |a van Kampen, Jeroen J A |e verfasserin |4 aut | |
| 700 | 1 | |a Rockx, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M A |e verfasserin |4 aut | |
| 700 | 1 | |a Katsikis, Peter D |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P G |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L |e verfasserin |4 aut | |
| 700 | 1 | |a Rokx, Casper |e verfasserin |4 aut | |
| 700 | 1 | |a Rijnders, Bart J A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 12(2021), 1 vom: 27. Mai, Seite 3189 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:27 |g month:05 |g pages:3189 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-021-23469-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 27 |c 05 |h 3189 | ||